- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02533050
Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP (CAPCORSAS)
Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With a Continuous Positive Airway Pressure System (CPAP). Etude CAPCORSAS
The presence of Obstructive Sleep Apnea Syndrome (OSAS) has a high frequency in patients victims of a coronary artery disease (CAD) (myocardial infarction, revascularization). Unlike patients seen in a sleep Laboratory with an impact on daytime functioning, CAD apneic patients do not complain in their daytime functioning. The objective of this study is to explore whether the objective cognitive assessment measures may be a good marker of the efficacy of CPAP treatment given to non-sleepy apneic CAD patients.
Coronary patients with an AHI between 15 and 40 / h will be treated (or not) after randomization with CPAP treatment. The expected results are: CPAP apneic coronary patients should have a positive impact on cognitive performance, particularly on attention span and working memory measured by improvement in the Paced Auditory Serial Addition Test score (PASAT score).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Saint-etienne, Frankreich, 42000
- Chu de Saint-Etienne
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient admitted to the Clinical Physiology Department of Exercise of the Saint Etienne University Hospital (myocardial infarction, coronary stenting or coronary artery bypass) and referred for care in cardiac rehabilitation
- A native French speaker
- No daytime sleepiness (ESS <or = 10)
- Signature of informed consent by the patient
Exclusion Criteria:
- Patients with a previous diagnosis of sleep apnea syndrome
- Patients with severe heart failure (stage III and IV of the NYHA)
- Patients with a neurodegenerative disease or other known cognitive disorders
- Presence of progressive disease other than coronary artery disease (cancer for example)
- Patients participating in other research that can change their cognitive function or drowsiness
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Patients treated
Patients with CAD and SAS.
This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10.
After randomization, they will be treated with CPAP treatment.
|
Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
|
|
Kein Eingriff: Patients non-treated
Patients with CAD and SAS.
This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10.
After randomization, they will be not treated.
|
|
|
Kein Eingriff: Control group
Patients with CAD but without SAS (AHI<15).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PASAT-4sec test score
Zeitfenster: Day 120
|
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability.
Single digits are presented every 4 seconds and the patient must add each new digit to the one immediately prior to it.
The score for the PASAT is the total number correct out of 60 possible answers.
|
Day 120
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Score Mini Mental State (MMS)
Zeitfenster: Day 120
|
It is a score obtained in psychometric tests.
This is a series of 30 questions that assesses cognitive and mnemonic ability of a person.
|
Day 120
|
|
Mean time (ms) obtained in a Continus Performance Test
Zeitfenster: Day 120
|
It is an other score obtained in psychometric tests.
It measures a person's sustained and selective attention (associated with impulsivity and distractibility).
|
Day 120
|
|
Percentage (%) obtained in a test measurement of the reaction time
Zeitfenster: Day 120
|
It is an other score obtained in psychometric tests.
It is a psychometer vigilance test.
|
Day 120
|
|
Mean time (ms) obtained in a test measurement of the reaction time
Zeitfenster: Day 120
|
It is an other score obtained in psychometric tests.
It is a psychometer vigilance test.
|
Day 120
|
|
Percentage (%) for a N-back working memory task
Zeitfenster: Day 120
|
It is an other score obtained in psychometric tests.
The subject is presented with a sequence of stimuli, and the task consists of indicating when the current stimulus matches the one from n steps earlier in the sequence.
|
Day 120
|
|
Average time (ms) for a N-back working memory task
Zeitfenster: Day 120
|
It is an other score obtained in psychometric tests.
The subject is presented with a sequence of stimuli, and the task consists of indicating when the current stimulus matches the one from n steps earlier in the sequence.
|
Day 120
|
|
AHI
Zeitfenster: Day 120
|
It is the number of apnea and hypopnea per hour.
It determined by polysomnography.
|
Day 120
|
|
Mean nocturnal oxygen saturation (%)
Zeitfenster: Day 120
|
It is a percentage index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
Minimal nocturnal oxygen saturation (%)
Zeitfenster: Day 120
|
It is an other percentage index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
The oxyhemoglobin desaturation index
Zeitfenster: Day 120
|
It is an other index of hypoxemia measured by a polysomnography.
It is expressed in desaturations / hour
|
Day 120
|
|
The time (min) spent with a SaO2 below 90%
Zeitfenster: Day 120
|
The arterial oxygen saturation (SaO2)is an other index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
Sleep fragmentation
Zeitfenster: Day 120
|
It is determined by a polysomnography.
|
Day 120
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Erkrankungen des Nervensystems
- Erkrankungen der Atemwege
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Atemstörungen
- Schlafstörungen, intrinsisch
- Dyssomnien
- Schlaf-Wach-Störungen
- Erkrankung
- Anzeichen und Symptome, Atmung
- Koronare Herzkrankheit
- Myokardischämie
- Koronare Krankheit
- Schlafapnoe-Syndrome
- Schlafapnoe, obstruktiv
- Syndrom
- Apnoe
- Akutes Koronar-Syndrom
Andere Studien-ID-Nummern
- 1308171
- 2013-A01635-40 (Andere Kennung: ANSM)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Obstruktive Schlafapnoe
-
Haseki Training and Research HospitalNoch keine RekrutierungRichards-Campbell Sleep-Fragebogen (RCSQ)
-
ElsanEuropean Clinical Trial Experts Network; Polyclinique PoitiersAbgeschlossenObstruktives Schlafapnoe-Syndrom | Hypnose | Drug Induce Sleep EndoscopyFrankreich
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityBeendetSchlafstörungen, intrinsisch | Schlaf-Wach-Störungen | Schlafstörungen, zirkadianer Rhythmus | Fortgeschrittenes Schlafphasensyndrom (ASPS) | Verzögertes Schlafphasensyndrom | Schichtarbeits-Schlafstörung | Verzögerte Schlafphase | Nicht-24-Stunden-Schlaf-Wach-Störung | Fortgeschrittenes Schlafphasensyndrom und andere BedingungenVereinigte Staaten
Klinische Studien zur CPAP treatment
-
Centre Hospitalier Intercommunal CreteilPr Xavier DURRMEYERNoch keine RekrutierungAtemnot bei NeugeborenenFrankreich
-
University of KansasChildren's Mercy Hospital Kansas City; Purdue UniversityRekrutierung
-
Escola Superior Saúde Fernando PessoaAktiv, nicht rekrutierend
-
State Key Laboratory of Respiratory DiseaseAbgeschlossenSchlafapnoe, obstruktiv | Kontinuierlicher positiver Atemwegsdruck | PolysomnographieChina
-
Johns Hopkins Bloomberg School of Public HealthUnited States Agency for International Development (USAID)AbgeschlossenDepression | Posttraumatische BelastungsstörungUkraine
-
IRCCS Eugenio MedeaAbgeschlossenZerebralparese | Gangstörungen, neurologischItalien
-
Chinese University of Hong KongAbgeschlossen
-
University of ZurichSwiss National Science FoundationAbgeschlossen
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)AbgeschlossenSchlafapnoe-Syndrome | Lungenkrankheit | SchlafenVereinigte Staaten
-
The Hospital for Sick ChildrenAbgeschlossenFettleibigkeit | Herzkreislauferkrankung | Obstruktive Schlafapnoe | SchlafstörungenKanada